Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ellen M van Dam"'
Autor:
Adam Brymora, Iain G Duggin, Leise A Berven, Ellen M van Dam, Basil D Roufogalis, Phillip J Robinson
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e50879 (2012)
RalA is a membrane-associated small GTPase that regulates vesicle trafficking. Here we identify a specific interaction between RalA and ERp57, an oxidoreductase and signalling protein. ERp57 bound specifically to the GDP-bound form of RalA, but not t
Externí odkaz:
https://doaj.org/article/e0485c883f5c42108cfec9d7570c0ecf
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Background A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an
Externí odkaz:
https://doaj.org/article/6402ece3f46c433b8dd6fe849ec705f0
Autor:
Truc T. Huynh, Ellen M. van Dam, Sreeja Sreekumar, Cedric Mpoy, Benjamin J. Blyth, Fenella Muntz, Matthew J. Harris, Buck E. Rogers
Publikováno v:
Pharmaceuticals, Vol 15, Iss 6, p 728 (2022)
The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging and therapy of prostate cancer using bombesin peptides that bind to the receptor with high affinity. Targeted copper theranostics (TCTs) using copper radionucli
Externí odkaz:
https://doaj.org/article/6b47add857c6406db5f89e77d7494c0d
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
Autor:
Peter Roselt, Nicholas Zia, Lachlan E. McInnes, Matthew Harris, Sue Jackson, Ellen M van Dam, Rodney J. Hicks, Carleen Cullinane, Benjamin Blyth, Paul S. Donnelly
Publikováno v:
Journal of Nuclear Medicine. 62:829-832
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1230414f29062c13cad490fbc31eeec2
https://doi.org/10.2967/jnumed.120.251579
https://doi.org/10.2967/jnumed.120.251579
Autor:
Jessica Van Zuylekom, Price Jackson, Ellen M van Dam, Kevin Kuan, Matthew Harris, Susan Jackson, Rodney J. Hicks, David Binns, Peter Roselt, Paul S. Donnelly, Carleen Cullinane, Charmaine M. Jeffery
Publikováno v:
Journal of Nuclear Medicine. 61:1800-1805
Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors. The diagnostic and therapeutic potential of 64Cu and 67Cu, respectively, offers the pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ad7880c251bab79a33c9f977d051c6c
https://doi.org/10.2967/jnumed.120.243543
https://doi.org/10.2967/jnumed.120.243543
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-14 (2021)
EJNMMI Research
EJNMMI Research
Background A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an attracti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103eff8cbc3eafe853ffc4e09dcaa7e9
https://doi.org/10.1186/s13550-021-00763-0
https://doi.org/10.1186/s13550-021-00763-0
Autor:
Lachlan E, McInnes, Carleen, Cullinane, Peter D, Roselt, Susan, Jackson, Benjamin J, Blyth, Ellen M, van Dam, Nicholas A, Zia, Matthew J, Harris, Rodney J, Hicks, Paul S, Donnelly
Publikováno v:
J Nucl Med
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, (64)Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e08fa07b08a6a14f0fe44bd798aba0ae
https://pubmed.ncbi.nlm.nih.gov/33067341
https://pubmed.ncbi.nlm.nih.gov/33067341
Autor:
Carleen, Cullinane, Charmaine M, Jeffery, Peter D, Roselt, Ellen M, van Dam, Susan, Jackson, Kevin, Kuan, Price, Jackson, David, Binns, Jessica, van Zuylekom, Matthew J, Harris, Rodney J, Hicks, Paul S, Donnelly
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(12)
Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors. The diagnostic and therapeutic potential of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43cb51e707062ba73c62fb0a75ee7c81
https://pubmed.ncbi.nlm.nih.gov/32414949
https://pubmed.ncbi.nlm.nih.gov/32414949
Autor:
Ellen M. van Dam, Jack U. Flanagan, Hilary Brooks, Amanda Khoury, Colin K. W. Watts, William A. Denny, Marie Dziadek, Darby G. Brooke, Lisa-Jane K. Graham
Publikováno v:
Bioorganic & Medicinal Chemistry. 22:1029-1039
High-throughput screening of a small-molecule library identified a 5-triazolo-2-arylpyridazinone as a novel inhibitor of the important glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Such inhibitors are of interest due to PF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c16f51cb59dbf5e96345a1393089ff
https://doi.org/10.1016/j.bmc.2013.12.041
https://doi.org/10.1016/j.bmc.2013.12.041
Autor:
Anna Mariana, Jennette A. Sakoff, Kelly A. Young, Luke R. Odell, Jayne Gilbert, Timothy A. Hill, Damien J. Keating, Aimee E. Novelle, Nick N. Gorgani, Phillip J. Robinson, Ngoc Chau, Megan Chircop, Ellen M. van Dam, James A. Daniel, Fiona M. Deane, Michael A. Cousin, Ainslie Whiting, Adam McCluskey, Annie Quan, Swetha Perera, Andrew B. McGeachie
Publikováno v:
ACS Chemical Biology. 8:1507-1518
Dynamin is required for clathrin-mediated endocytosis (CME). Its GTPase activity is stimulated by phospholipid binding to its PH domain, which induces helical oligomerization. We have designed a series of novel pyrimidine-based "Pyrimidyn" compounds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e91e1ed80da1877f3552c09606e540c
https://doi.org/10.1021/cb400137p
https://doi.org/10.1021/cb400137p